Key Points
- CEO Tien-Li Lee bought 7,000 shares at $14.48 on Dec. 11 for $101,360, boosting his ownership to 1,551,613 shares (a 0.45% increase) worth roughly $22.47 million.
- AARD stock opened at $14.43 (down 7.6%), trades in a 52‑week range of $4.88–$19.58, has a market cap of $314.14 million and a negative trailing P/E of -6.81.
- Analysts show a consensus of "Moderate Buy" with an average price target of $32.44, though individual ratings vary from sell to strong‑buy (Raymond James target $47).
Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) CFO Nelson Sun purchased 3,000 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average price of $14.40 per share, with a total value of $43,200.00. Following the completion of the transaction, the chief financial officer owned 108,484 shares of the company's stock, valued at $1,562,169.60. The trade was a 2.84% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Aardvark Therapeutics Stock Down 7.6%
AARD stock opened at $14.43 on Friday. Aardvark Therapeutics, Inc. has a twelve month low of $4.88 and a twelve month high of $19.58. The stock has a market capitalization of $314.14 million and a price-to-earnings ratio of -6.81. The firm's fifty day simple moving average is $11.93 and its two-hundred day simple moving average is $11.70.
Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last released its earnings results on Thursday, November 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.07.
Institutional Investors Weigh In On Aardvark Therapeutics
Hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Aardvark Therapeutics during the second quarter valued at $42,000. New York State Common Retirement Fund bought a new position in Aardvark Therapeutics during the 2nd quarter worth about $99,000. Bank of America Corp DE increased its position in Aardvark Therapeutics by 72.9% during the 2nd quarter. Bank of America Corp DE now owns 7,989 shares of the company's stock valued at $108,000 after purchasing an additional 3,369 shares during the period. Walleye Capital LLC bought a new stake in shares of Aardvark Therapeutics in the 1st quarter valued at about $88,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Aardvark Therapeutics in the 1st quarter worth approximately $153,000.
Wall Street Analysts Forecast Growth
AARD has been the subject of several recent analyst reports. BTIG Research started coverage on Aardvark Therapeutics in a research report on Friday, November 7th. They set a "buy" rating and a $26.00 target price for the company. Stifel Nicolaus started coverage on Aardvark Therapeutics in a report on Monday, September 29th. They set a "buy" rating and a $24.00 price objective for the company. Jones Trading assumed coverage on Aardvark Therapeutics in a research note on Wednesday, October 1st. They issued a "buy" rating and a $33.00 target price on the stock. William Blair initiated coverage on shares of Aardvark Therapeutics in a research note on Friday. They set an "outperform" rating for the company. Finally, Bank of America reduced their price target on shares of Aardvark Therapeutics from $26.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, August 28th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Aardvark Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $32.44.
View Our Latest Report on Aardvark Therapeutics
About Aardvark Therapeutics
(
Get Free Report)
Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
